Clinical Trials Logo

Multi Organ Failure clinical trials

View clinical trials related to Multi Organ Failure.

Filter by:

NCT ID: NCT01315782 Recruiting - Sepsis Clinical Trials

Alveolar Dead Space as Predictor of Organ Failure in Severe Sepsis

Start date: December 2016
Phase:
Study type: Observational

This is an observational study to understand the changes in alveolar dead space in medical critically ill patients with severe infection (severe sepsis) requiring mechanical ventilation and the possibility to predict multi-organ failure. The measurement of alveolar dead space used to require sophisticated equipment and time. New ventilators have microprocessors that allow rapid mathematical calculation with minimal intervention.

NCT ID: NCT00752245 Withdrawn - Renal Failure Clinical Trials

Uremic Toxins in the Intensive Care Unit (ICU): Patients With Sepsis

Start date: July 31, 2008
Phase: N/A
Study type: Interventional

Study of the kinetics of uremic toxins in the ICU patients with acute renal failure, in order to optimize the dialysis dose: patients with sepsis/multi-organ failure. The sampling of blood and dialysate will be done during dialyses with different durations (4, 6 and 8h)

NCT ID: NCT00264368 Terminated - Clinical trials for Cytomegalovirus Infections

Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy

Start date: December 2005
Phase: Phase 4
Study type: Interventional

In order to optimize anti-cytomegalovirus (CMV) treatment with ganciclovir (GCV), in patients with multi organ failure treated with continuous renal replacement therapy (RRT), more information about ganciclovir pharmacokinetics in this setting is needed. The primary objective is to describe the pharmacokinetics of ganciclovir in critically ill patients with acute renal failure treated with continuous renal replacement therapy, with a special emphasis on the extra-renal clearance and distribution volume. Secondary objectives are to investigate if any co-factors, such as serum creatinine, weight, general hydration status, rest function of the native kidneys, etc. can help to describe the pharmacokinetics of GCV in these patients on continuous RRT as well as the relative influence of filtrations and dialysis on GCV elimination during different modalities of the treatment.